{"filing":{"accession_number":"0001648257-26-000057","cik":"0001648257","ticker":"HMDCF","company_name":"HUTCHMED (China) Ltd","form":"6-K","filing_date":"2026-09-03","report_date":"2026-09-03","primary_document":"hcm-20260903x6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1648257/000164825726000057/hcm-20260903x6k.htm"},"events":[{"id":31432,"run_id":28838,"accession_number":"0001648257-26-000057","anchor_item_number":"EX-99.1","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"HUTCHMED has entered into an exclusive development and license agreement with GSK subsidiary for HMPL-A830, a first-in-class KRAS-EGFR antibody conjugate. The agreement includes a $110 million upfront payment and up to $1.295 billion in total milestone and royalty payments, representing a material licensing transaction that grants GSK worldwide rights (excluding Greater China) to develop and commercialize the asset. This constitutes a material disposition of rights and a significant commercial arrangement affecting the registrant's asset portfolio and revenue potential.","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-09-03","form":"6-K","submitted_at":null,"items":[{"id":34305,"accession_number":"0001648257-26-000057","item_number":"EX-99.1","item_title":"hcm-20260903xex99d1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"HUTCHMED has entered into an exclusive development and license agreement with GSK subsidiary for HMPL-A830, a first-in-class KRAS-EGFR antibody conjugate. The agreement includes a $110 million upfront payment and up to $1.295 billion in total milestone and royalty payments, representing a material licensing transaction that grants GSK worldwide rights (excluding Greater China) to develop and commercialize the asset. This constitutes a material disposition of rights and a significant commercial arrangement affecting the registrant's asset portfolio and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-03T10:06:42.057495+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":34305,"accession_number":"0001648257-26-000057","item_number":"EX-99.1","item_title":"hcm-20260903xex99d1.htm","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"HUTCHMED has entered into an exclusive development and license agreement with GSK subsidiary for HMPL-A830, a first-in-class KRAS-EGFR antibody conjugate. The agreement includes a $110 million upfront payment and up to $1.295 billion in total milestone and royalty payments, representing a material licensing transaction that grants GSK worldwide rights (excluding Greater China) to develop and commercialize the asset. This constitutes a material disposition of rights and a significant commercial arrangement affecting the registrant's asset portfolio and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-03T10:06:42.057495+00:00","company_name":"HUTCHMED (China) Ltd","ticker":"HMDCF","filing_date":"2026-09-03"}]}